Trevi Therapeutics Aktie

Kaufen

Verkaufen

7,20 USD -0,21 USD -2,77 %

nachbörslich31.07.2025

BTT

Aktien, ETFs, Sparpläne & Kryptos zu Top-Konditionen beim Testsieger von finanztip.de handeln!

JETZT LOSLEGEN

Bei einem anderen Broker handeln Smartphone

Marktkap.771,89 Mio. EUR

Div. Rendite0,00%

WKNA2PHHF

ISINUS89532M1018

SymbolTRVI

Trevi Therapeutics Aktien News

Sortieren:Datum Meistgelesen

31.07.25PR NewswireTrevi Therapeutics to Report Second Quarter 2025 Financial Results and Provide a Corporate Update on August 7, 2025

29.07.25PR NewswireTrevi Therapeutics to Participate in Upcoming August Conferences

11.07.25ZacksWall Street Analysts Predict a 231.05% Upside in Trevi Therapeutics (TRVI): Here's What You Should Know

01.07.25PR NewswireTrevi Therapeutics to Attend Leerink Partners Therapeutics Forum: I&I and Metabolism

02.06.25BenzingaTrevi Therapeutics Showcases Drug That Cuts Cough Frequency In Lung Disease Patients

02.06.25PR NewswireTrevi Therapeutics Announces Positive Topline Results from the Phase 2b CORAL Trial of Haduvio in Patients with Idiopathic Pulmonary Fibrosis Chronic Cough

01.06.25PR NewswireTrevi Therapeutics to Host Conference Call and Webcast on June 2nd to Share Topline Results from the Phase 2b CORAL Trial of Haduvio in Patients with Idiopathic Pulmonary Fibrosis Chronic Cough

29.05.25PR NewswireTrevi Therapeutics to Participate in Upcoming June Conferences

28.05.25TraderFoxKursziele

TOP-5-Kursziele der Analysten am 28.05.25

20.05.25PR NewswireTrevi Therapeutics Announces Additional Analyses from Phase 2a RIVER Trial of Haduvio in Patients with Refractory Chronic Cough

14.05.25ZacksWall Street Analysts See a 195.05% Upside in Trevi Therapeutics (TRVI): Can the Stock Really Move This High?

10.05.25finanzen.netTrevi Therapeutics stellte das Zahlenwerk zum vergangenen Quartal vor

08.05.25PR NewswireTrevi Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Updates

07.05.25BenzingaEarnings Preview For Trevi Therapeutics

01.05.25PR NewswireTrevi Therapeutics to Report First Quarter 2025 Financial Results and Provide a Corporate Update on May 8, 2025

03.04.25PR NewswireTrevi Therapeutics to Participate in Upcoming April Investor Conferences

21.03.25finanzen.netTrevi Therapeutics präsentierte Bilanzzahlen zum jüngsten Jahresviertel

18.03.25PR NewswireTrevi Therapeutics Reports Fourth Quarter and Year End 2024 Financial Results and Provides Business Updates

11.03.25PR NewswireTrevi Therapeutics to Report Fourth Quarter and Year End 2024 Financial Results and Provide a Corporate Update on March 18, 2025

10.03.25BenzingaRedfin, Mineralys Therapeutics, Trevi Therapeutics And Other Big Stocks Moving Higher On Monday

10.03.25BenzingaTrevi Therapeutics Reveals Positive Data From Mid-Stage Study For Chronic Cough Candidate, Stock Jumps

10.03.25PR NewswireTrevi Therapeutics Announces Positive Topline Results from the Phase 2a RIVER Trial of Haduvio in Patients with Refractory Chronic Cough

09.03.25PR NewswireTrevi Therapeutics to Host Conference Call and Webcast on March 10th to Share Topline Results from the Phase 2a RIVER Trial of Haduvio in Patients with Refractory Chronic Cough

27.02.25PR NewswireTrevi Therapeutics to Participate in Upcoming March Investor Conferences

25.02.25PR NewswireTrevi Therapeutics Completes Enrollment for Phase 2b CORAL Trial of Haduvio in Idiopathic Pulmonary Fibrosis Patients with Chronic Cough

30.01.25PR NewswireTrevi Therapeutics to Participate in Upcoming February Investor Conferences

08.01.25ZacksWhat Makes Trevi Therapeutics (TRVI) a New Buy Stock

08.01.25PR NewswireTrevi Therapeutics Announces Company Updates Ahead of 14th Annual LifeSci Partners Corporate Access Event Held During the J.P. Morgan Healthcare Conference

12.12.24BenzingaWhy Is Cough-Focused Trevi Therapeutics Stock Skyrocketing On Thursday?

12.12.24PR NewswireTrevi Therapeutics Announces Positive Outcome from Sample Size Re-estimation Resulting in No Change to the Current Sample Size for the Phase 2b CORAL Trial in Idiopathic Pulmonary Fibrosis Patient...

03.12.24PR NewswireTrevi Therapeutics Announces Positive Topline Results from Human Abuse Potential Study of Oral Nalbuphine

21.11.24PR NewswireTrevi Therapeutics to Participate in Piper Sandler 36th Annual Healthcare Conference

08.11.24finanzen.netTrevi Therapeutics: Bilanzvorlage zum letzten Quartal

06.11.24PR NewswireTrevi Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Updates

30.10.24PR NewswireTrevi Therapeutics to Report Third Quarter 2024 Financial Results and Provide a Corporate Update on November 6, 2024

21.10.24PR NewswireTrevi Therapeutics Completes Enrollment for Phase 2a RIVER Trial in Refractory Chronic Cough

15.10.24PR NewswireTrevi Therapeutics to Participate in Upcoming Commercial and Investor Conferences

03.10.24PR NewswireTrevi Therapeutics Provides Update on Haduvio's Clinical Development Program

30.09.24PR NewswireTrevi Therapeutics Announces Appointment of James V. Cassella, Ph.D., as Chief Development Officer

26.09.24PR NewswireTrevi Therapeutics Announces Additional Analyses of Cough Relief Time from Ph2a CANAL Trial Accepted for Oral Presentation at CHEST 2024

Trevi Therapeutics News

Trevi Therapeutics News: auf dieser Seite finden Sie alle Trevi Therapeutics News und Nachrichten zur Trevi Therapeutics Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Trevi Therapeutics News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Trevi Therapeutics News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.